Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to ... Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. 詳細を表示
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0134 | -1.57647058824 | 0.85 | 1.05 | 0.8 | 5044529 | 1.00422269 | CS |
4 | 0.0122 | 1.47986414362 | 0.8244 | 1.05 | 0.8 | 1296981 | 1.00050496 | CS |
12 | -0.4634 | -35.6461538462 | 1.3 | 1.3 | 0.702 | 596473 | 0.9902899 | CS |
26 | -0.9934 | -54.2841530055 | 1.83 | 3.8 | 0.702 | 1310986 | 1.88637833 | CS |
52 | -17.7664 | -95.5028758802 | 18.603 | 25.26 | 0.702 | 802124 | 2.87118716 | CS |
156 | -8798.1634 | -99.9904921014 | 8799 | 10237.5 | 0.702 | 1263468 | 800.46701633 | CS |
260 | -8798.1634 | -99.9904921014 | 8799 | 10237.5 | 0.702 | 1263468 | 800.46701633 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約